-transparent.png){kind=logo}
Thirty-eight metastatic breast cancer patients were treated with aminoglutethimide. All patients had progressive metastatic disease following initial response to Tamoxifen therapy. Thirty-two patients were evaluable for response, of these, two patients (6%) had complete remission, 13 patients (41%) had partial response, and six patients (19%) had stable disease. Eleven patients (34%) had progressive disease. The most common side effects were transient skin rash, lethargy or dizziness. Four patients' (11%) treatment was discontinued because of either skin rash or dizziness within the first two weeks of the study. These data show that aminoglutethimide is an effective agent following tamoxifen therapy.
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
October 1992,
Gan to kagaku ryoho. Cancer & chemotherapy,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
September 1984,
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
January 1982,
The Medical journal of Australia,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
May 1983,
British medical journal (Clinical research ed.),
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
August 1982,
Cancer research,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
December 1984,
Harefuah,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
August 1982,
Cancer research,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
August 1985,
Southern medical journal,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
November 1984,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A U Buzdar, and
K C Powell, and
S S Legha, and
G R Blumenschein
February 1982,
Cancer,
